Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Inhaled Levosimendan
NCT06387862Phase 2Unknown
- Sponsor
- UZ Brussel
- Start
- Feb 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levosimendan in left ventricular dysfunction (2 arms), sponsored by UZ Brussel. Primary endpoints: Bioavailability of inhaled levosimendan at 10 hours, Time-to-peak of inhaled levosimendan at 10 hours and 1 more. Status: unknown.
02
Drugs
levosimendan
03
Conditions
left ventricular dysfunction
Beyond the preview
Go deeper on NCT06387862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387862.